PLG and COVID-19: With the use of network pharmacology and molecular docking in the present work, it was found that the reported compounds of VN can possibly affect the molecular pathogenesis of COVID-19 by acting on plasminogen activator inhibitor-1, plasminogen, and cathepsin B. However, the limitation of this study relies on the fact that these are computational predictions and further experimentations are needed.